| 1 |
34896359 | Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use. | 2022 Mar |
3 |
| 2 |
35600875 | The Role of Geranylgeraniol in Managing Bisphosphonate-Related Osteonecrosis of the Jaw. | 2022 |
1 |
| 3 |
32057422 | NMR for screening and a biochemical assay: Identification of new FPPS inhibitors exerting anticancer activity. | 2020 May |
2 |
| 4 |
32537808 | Fragment-Based Discovery of Non-bisphosphonate Binders of Trypanosoma brucei Farnesyl Pyrophosphate Synthase. | 2020 Nov 2 |
1 |
| 5 |
32569873 | Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. | 2020 Oct |
1 |
| 6 |
30036888 | QSAR Models for Nitrogen Containing Monophosphonate and Bisphosphonate Derivatives as Human Farnesyl Pyrophosphate Synthase Inhibitors Based on Monte Carlo Method. | 2019 Mar |
1 |
| 7 |
31023104 | A patent review of bisphosphonates in treating bone disease. | 2019 May |
2 |
| 8 |
29080272 | 3D-QSAR, molecular docking, and ONIOM studies on the structure-activity relationships and action mechanism of nitrogen-containing bisphosphonates. | 2018 Mar |
2 |
| 9 |
29683099 | Identifying Potential Therapeutics for Osteoporosis by Exploiting the Relationship between Mevalonate Pathway and Bone Metabolism. | 2018 |
1 |
| 10 |
26314394 | Protonation State and Hydration of Bisphosphonate Bound to Farnesyl Pyrophosphate Synthase. | 2015 Sep 24 |
2 |
| 11 |
24172032 | Thermodynamic evaluation of the binding of bisphosphonates to human farnesyl pyrophosphate synthase. | 2014 |
2 |
| 12 |
24598749 | Structural and thermodynamic basis of the inhibition of Leishmania major farnesyl diphosphate synthase by nitrogen-containing bisphosphonates. | 2014 Mar |
1 |
| 13 |
24699741 | Crystallization and preliminary neutron diffraction experiment of human farnesyl pyrophosphate synthase complexed with risedronate. | 2014 Apr |
2 |
| 14 |
23533771 | Bisphosphonates and cancer: what opportunities from nanotechnology? | 2013 |
1 |
| 15 |
23794630 | Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses. | 2013 Aug 1 |
1 |
| 16 |
21864230 | The chemistry of bisphosphonates: from antiscaling agents to clinical therapeutics. | 2012 Feb |
1 |
| 17 |
22884353 | Design of potent bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase via targeted interactions with the active site 'capping' phenyls. | 2012 Sep 15 |
2 |
| 18 |
21111853 | Biochemical and molecular mechanisms of action of bisphosphonates. | 2011 Jul |
1 |
| 19 |
21145999 | Denosumab and bisphosphonates: different mechanisms of action and effects. | 2011 Apr 1 |
1 |
| 20 |
21237288 | Inhibition of the isoprenoid biosynthesis pathway; detection of intermediates by UPLC-MS/MS. | 2011 Apr |
1 |
| 21 |
21247791 | Geranylgeraniol - a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw. | 2011 Mar |
1 |
| 22 |
21420384 | Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells. | 2011 Apr 22 |
3 |
| 23 |
21497677 | The relationship between the chemistry and biological activity of the bisphosphonates. | 2011 Jul |
2 |
| 24 |
22091898 | Bisphosphonates and osteonecrosis of the jaw. | 2011 Dec |
1 |
| 25 |
20299227 | Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs). | 2010 Apr 1 |
1 |
| 26 |
20450493 | Sterol-regulatory-element-binding protein 2 and nuclear factor Y control human farnesyl diphosphate synthase expression and affect cell proliferation in hepatoblastoma cells. | 2010 Jul 15 |
1 |
| 27 |
20533067 | Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease. | 2010 Nov |
1 |
| 28 |
20544107 | Discovery of potent inhibitor for farnesyl pyrophosphate synthase in the mevalonate pathway. | 2010 Aug 7 |
1 |
| 29 |
20722616 | Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. | 2010 |
1 |
| 30 |
19016713 | Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. | 2009 Jan |
1 |
| 31 |
19233551 | Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells. | 2009 Jun 8 |
1 |
| 32 |
19371349 | Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. | 2009 Jun |
1 |
| 33 |
19665949 | Analysis of endogenous ATP analogs and mevalonate pathway metabolites in cancer cell cultures using liquid chromatography-electrospray ionization mass spectrometry. | 2009 Oct 1 |
1 |
| 34 |
19699819 | The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro. | 2009 Dec |
2 |
| 35 |
19810397 | Bisphosphonates and osteonecrosis of the jaw--current thoughts. | 2009 Sep |
1 |
| 36 |
18214569 | Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. | 2008 Jun |
2 |
| 37 |
18327899 | Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. | 2008 Apr 10 |
1 |
| 38 |
18454049 | Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. | 2008 Apr |
1 |
| 39 |
18494934 | Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. | 2008 Jun |
2 |
| 40 |
16996129 | Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. | 2007 Mar |
1 |
| 41 |
17277961 | [Introduction to bisphosphonates. History and functional mechanisms]. | 2007 Feb |
1 |
| 42 |
17959891 | Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. | 2007 Nov |
1 |
| 43 |
18056045 | Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. | 2007 Nov |
2 |
| 44 |
22460750 | Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders. | 2007 Jan |
1 |
| 45 |
16216433 | Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy. | 2006 |
1 |
| 46 |
16650801 | Recent advances in understanding the mechanism of action of bisphosphonates. | 2006 Jun |
1 |
| 47 |
16684881 | The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. | 2006 May 16 |
2 |
| 48 |
16892359 | Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. | 2006 Feb |
3 |
| 49 |
16956297 | Investigation of the catalytic mechanism of farnesyl pyrophosphate synthase by computer simulation. | 2006 Sep 14 |
1 |
| 50 |
17062705 | Molecular mechanisms of action of bisphosphonates: current status. | 2006 Oct 15 |
1 |